NASDAQ
INVA

Innoviva Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Innoviva Inc Stock Price

Vitals

Today's Low:
$12.425
Today's High:
$12.54
Open Price:
$12.45
52W Low:
$10.64
52W High:
$13.9
Prev. Close:
$12.5
Volume:
439027

Company Statistics

Market Cap.:
$813.72 million
Book Value:
8.51
Revenue TTM:
$290.42 million
Operating Margin TTM:
42.76%
Gross Profit TTM:
$276.11 million
Profit Margin:
80.35%
Return on Assets TTM:
6.88%
Return on Equity TTM:
35.19%

Company Profile

Innoviva Inc had its IPO on 2004-10-05 under the ticker symbol INVA.

The company operates in the Healthcare sector and Biotechnology industry. Innoviva Inc has a staff strength of 101 employees.

Stock update

Shares of Innoviva Inc opened at $12.45 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $12.43 - $12.54, and closed at $12.44.

This is a -0.48% slip from the previous day's closing price.

A total volume of 439,027 shares were traded at the close of the day’s session.

In the last one week, shares of Innoviva Inc have slipped by -2.96%.

Innoviva Inc's Key Ratios

Innoviva Inc has a market cap of $813.72 million, indicating a price to book ratio of 1.4438 and a price to sales ratio of 2.4232.

In the last 12-months Innoviva Inc’s revenue was $290.42 million with a gross profit of $276.11 million and an EBITDA of $138.50 million. The EBITDA ratio measures Innoviva Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Innoviva Inc’s operating margin was 42.76% while its return on assets stood at 6.88% with a return of equity of 35.19%.

In Q2, Innoviva Inc’s quarterly earnings growth was a positive 45% while revenue growth was a negative 25.2%.

Innoviva Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
4.6468
PEG
0.24

Its diluted EPS in the last 12-months stands at $2.69 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0.24. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Innoviva Inc’s profitability.

Innoviva Inc stock is trading at a EV to sales ratio of 3.1313 and a EV to EBITDA ratio of 2.6518. Its price to sales ratio in the trailing 12-months stood at 2.4232.

Innoviva Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$1.12 billion
Total Liabilities
$39.40 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Innoviva Inc ended 2024 with $1.12 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.12 billion while shareholder equity stood at $555.09 million.

Innoviva Inc ended 2024 with $0 in deferred long-term liabilities, $39.40 million in other current liabilities, 653000.00 in common stock, $-168766000.00 in retained earnings and $14.88 million in goodwill. Its cash balance stood at $173.03 million and cash and short-term investments were $173.03 million. The company’s total short-term debt was $1,226,000 while long-term debt stood at $445.20 million.

Innoviva Inc’s total current assets stands at $323.54 million while long-term investments were $433.00 million and short-term investments were $-397940000.00. Its net receivables were $81.00 million compared to accounts payable of $4.59 million and inventory worth $46.85 million.

In 2024, Innoviva Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Innoviva Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$12.44
52-Week High
$13.9
52-Week Low
$10.64
Analyst Target Price
$14

Innoviva Inc stock is currently trading at $12.44 per share. It touched a 52-week high of $13.9 and a 52-week low of $13.9. Analysts tracking the stock have a 12-month average target price of $14.

Its 50-day moving average was $13.02 and 200-day moving average was $12.6 The short ratio stood at 17.48 indicating a short percent outstanding of 0%.

Around 133.5% of the company’s stock are held by insiders while 11039% are held by institutions.

Frequently Asked Questions About Innoviva Inc

The stock symbol (also called stock or share ticker) of Innoviva Inc is INVA

The IPO of Innoviva Inc took place on 2004-10-05

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
Ferrovial SA (FRRVY)
$31
0.37
+1.21%
$19.21
0.48
+2.56%
$19.47
-0.05
-0.26%
$11.09
0.05
+0.45%
$214.77
-1.82
-0.84%
$61.01
1.19
+1.99%
$16.09
0.25
+1.58%
$15.01
-0.68
-4.33%
$665.9
-42.7
-6.03%
$8.15
-0.15
-1.81%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Address

1350 Old Bayshore Highway, Burlingame, CA, United States, 94010